Journal
MEDICINAL RESEARCH REVIEWS
Volume 40, Issue 1, Pages 431-458Publisher
WILEY
DOI: 10.1002/med.21624
Keywords
animal model; mechanism; sporadic Alzheimer's disease
Categories
Funding
- National Natural Scientific Foundation Committee [81671264]
- ITSP-Guangdong-Hong-Kong Technology Cooperation Funding Scheme [GHP/012/16GD, JCYJ20160331141459373]
- Guangzhou Scientific Foundation Committee [201704020222, 201807010094]
Ask authors/readers for more resources
Alzheimer's disease (AD), the most common form of dementia, is a progressive neurodegenerative disease. In the past decades, numbers of promising drug candidates showed significant anti-AD effects in preclinical studies but failed in clinical trials. One of the major reasons might be the limitation of appropriate animal models for evaluating anti-AD drugs. More than 95% of AD cases are sporadic AD (sAD). However, the anti-AD drug candidates were mainly tested in the familial AD (fAD) animal models. The diversity between the sAD and fAD might lead to a high failure rate during the development of anti-AD drugs. Therefore, an ideal sAD animal model is urgently needed for the development of anti-AD drugs. Here, we summarized the available sAD animal models, including their methodology, pathologic features, and potential underlying mechanisms. The limitations of these sAD animal models and future trends in the field were also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available